Rich Whitworth
|
Partnerships and strategic agreements are common in the pharma industry. But one particular announcement last month gave me
cause to raise my eyebrows and smile.
I like fast cars and so too, it would seem, does GlaxoSmithKline's CEO Andrew Witty because the company is embarking on a
long-term strategic partnership with the McLaren group, which is best known for its Formula 1 racing cars. The phrase "best
of British" springs to mind and both companies seem extremely proud of the partnership.
The aim for GSK? Applying McLaren's engineering and technical expertise to production lines to reduce breakdowns and improve
costs, amongst other things.
A state-of-the-art facility planned for 2013 called The McLaren GSK Centre for Applied Performance will allow scientists,
engineers, and technologists from both camps to share ideas and collaborate on innovative, dynamic, and exciting joint working
projects.
The R&D organization will examine whether real-time monitoring technologies can be applied to human studies. Meanwhile, the
GSK Consumer Healthcare business will work with McLaren's "Mission Control" unit to enable faster responses to competitor
activity and customer needs.
Some might say that it smacks of a marketing stunt, but which pharma company wouldn't want to be associated with such a fast-paced,
exciting, technologically advanced, continually improving world?
What next? Sanofi and Red Bull Racing? The race to the checkered flag is on!
Rich Whitworth is an editor of Pharmaceutical Technology.
